Pharmaceutical cybersecurity
Pharmaceutical Cybersecurity
Expertise for Your Team
Protect confidential research and sensitive clinical information. Strengthen access to laboratory, manufacturing, and quality systems. Turn security findings into controlled improvements with clear owners and evidence of completion.
Your information moves between research teams, clinical partners, laboratories, manufacturing sites, and technology providers.
A single workflow may depend on several organisations, each with different systems and responsibilities. Security work needs to account for these relationships and the controls that keep important records usable and trustworthy.
Nestack helps you review selected environments, identify practical improvements, and coordinate the work with your IT, quality, clinical, and operational teams. Start with one system or workflow, or discuss a dedicated engineer to maintain an agreed security programme.
Three ways to work with Nestack
- 01
Scoped security assessment
Examine a defined application, environment, access process, or recovery scenario, and receive prioritised findings, supporting evidence, and recommended next steps.
- 02
Dedicated security engineer
Add an engineer with an agreed technical profile, schedule, reporting line, and backlog, with specialist support where validation, clinical, laboratory, or operational expertise is needed.
- 03
Ongoing security improvement
Coordinate remediation, access reviews, retesting, and evidence updates through your approved processes, with responsibilities agreed before work starts.
Security assessment and remediation support work alongside your quality and validation processes. They do not replace those processes or their approval responsibilities.
02Who we help
Security support for the organisations advancing and supplying medicines
Research, clinical development, laboratories, manufacturing, and external partners each hold different information and responsibilities. We shape the work around your role and the systems you control.
Protect discovery work, intellectual property, development plans, clinical collaboration, and regulatory information. Review the systems and external relationships supporting your programmes.
Assess access boundaries between sponsors, studies, sites, and staff. Review approved clinical applications, document exchange, and service-provider integrations with the responsible study teams.
Review business IT, quality-system access, manufacturing-support applications, and vendor connections. Define specialist arrangements for equipment, automation, and validated environments.
Assess selected laboratory data systems, research platforms, portals, cloud services, and integrations. Coordinate instrument-related work and product-specific testing with the people who own and support those systems.
Connect security with the right decision owners
We work with IT, research, clinical operations, quality, validation and manufacturing teams, and agree decision owners at the start. Clinical decisions, quality disposition and product release stay with your authorised functions.
03Pharmaceutical security risk assessment
Understand which exposures matter to your programmes and operations
An assessment should connect technical issues with the information and workflows they could affect.
We review the agreed scope with your business and system owners, identify gaps, and build a practical improvement backlog, clearly distinguishing tested controls, documentary observations, assumptions, and exclusions.
Assessment scope
- 01
Research and intellectual property
Discovery datasets, formulations, development documents, collaboration spaces and external sharing.
- 02
Clinical and regulatory workflows
Applications, roles and providers supporting study information, submissions and safety-related records.
- 03
Laboratory and manufacturing dependencies
Business IT, laboratory software, quality platforms and operational connections, each tested appropriately.
- 04
Partner and privileged access
Permissions of employees, contract research organisations, manufacturers, contractors and providers.
- 05
Business interruption and recovery
Important systems, provider dependencies, recovery assumptions and decision owners.
01Former research partner retains access
Possible consequence:Disclosure of confidential development work
Proposed action:Review recipients and revoke obsolete access
Completion evidence:Approved access list and verification
Owner to agree:Research + IT
02Test portal permits cross-study record access
Possible consequence:Exposure of another study's information
Proposed action:Correct study-level authorisation
Completion evidence:Synthetic-account retest
Owner to agree:Application owner
03Instrument support account remains enabled
Possible consequence:Uncontrolled remote access path
Proposed action:Introduce approved, time-limited access
Completion evidence:Access configuration and session evidence
Owner to agree:Lab owner + IT
04Recovery exercise omits record history
Possible consequence:Restored records lack necessary context
Proposed action:Include required history and metadata in test scope
Completion evidence:Documented reconciliation results
Owner to agree:System owner + QA
05AI assistant retrieves restricted dossiers
Possible consequence:Confidential material disclosed to wrong users
Proposed action:Preserve source permissions in retrieval
Completion evidence:Role-based evaluation evidence
Owner to agree:AI owner + security
These are fictional examples showing how findings could be presented, not incidents or results from Nestack customers.
04Clinical, research application, and API security
Review who can see records and perform sensitive actions
We assess the agreed boundaries around the applications and interfaces connecting staff, investigators, service providers and research partners, using controlled test accounts and approved data.
05Cloud, laboratory IT, and manufacturing-system security
Strengthen the environments connecting research and operations
06Identity, researcher, and third-party access
Keep permissions aligned with current responsibilities
Projects, studies, partnerships and roles change. We check that people and service accounts keep only the access they need, and that high-impact permissions are controlled.
07Ransomware and pharmaceutical recovery readiness
Prepare to recover systems and establish confidence in restored information
08Data integrity controls and assurance readiness
Make technical controls and their evidence easier to review
Security engineering can help protect records against unauthorised access or change. Data integrity also depends on processes, people, and the intended use of the system, so we work with your quality and validation teams on agreed technical controls and evidence.
A security assessment does not provide FDA approval, a guarantee of Part 11 or Annex 11 compliance, complete good-practice (GxP) validation, or authority to approve product quality.
What the engagement can cover
09CRO, CDMO, laboratory, and supplier security
Review the access and dependencies created by external relationships
Outsourced research, trials, testing, manufacturing and technology services introduce data and access dependencies. We prioritise reviews around those that matter to your programmes.
- 01Partner inventory and criticalityWhich providers support priority activities, and the consequences if their service fails.
- 02Information exchangeApproved channels for research results, study documents, specifications and confidential data.
- 03Delegated accessAccess granted to CROs, CDMOs, laboratories, support vendors and their personnel.
- 04Integration securityAPI identities, file exchanges, cloud connections and remote-support arrangements.
- 05Evidence and responsibility reviewSupplier evidence, open questions, incident contacts and responsibilities for procurement and quality.
- 06Change, transition, and exitAccess removal, record availability, service transition and data return when relationships change.
10 · Pharmaceutical AI and agent security
Control the information and actions available to AI-assisted workflows
Research assistants, clinical-document tools, regulatory copilots, and operational agents can connect to sensitive material and consequential actions. We assess the security boundaries around selected AI applications and the tools they can use.
A successful security evaluation does not establish scientific validity, clinical suitability, factual accuracy, or regulatory acceptability. An assistant should never independently approve batches, clinical decisions, or regulatory submissions.
What the review can cover
Across the pharmaceutical lifecycle
Security priorities across the pharmaceutical lifecycle
Eight moments to revisit as programmes and systems change, each with the service on this page that addresses it.
References reviewed October 2026Priorities for assessment, not legal or regulatory advice. Applicability is established for each client by qualified quality, regulatory and legal owners.
11Hire a dedicated pharmaceutical cybersecurity engineer
Hire a Dedicated Cybersecurity Engineer
An engineer selected for your priority systems, with the technical profile, interview, reporting line, schedule and access boundaries agreed before assignment. Engineers in India work through approved client-controlled access.
01Own the agreed security work
- Findings, priorities, owners and verification
- Authorised reviews and remediation tasks
- Organised, minimised evidence
- Escalating decisions beyond their authority
02Work with your specialists
- IT, quality, research and clinical owners
- Developers, providers and manufacturing teams
- Approved change and evidence processes
- Validation and response specialists
03Make progress visible
- Completed work, risks and decisions needed
- Retest results and limitations
- Access and assessment documentation
- Handover material and a current backlog
One engineer is not a complete security operations centre or every pharmaceutical assurance discipline. Site work, instrument testing, formal validation and emergency response may need additional specialists.
12Frequently asked questions
Frequently asked questions
Showing 19 of 19 questions
Yes. Agree the role and review the proposed engineer's relevant experience and working approach. Confirm availability, specialist support, responsibilities, and the start date in the proposal.
Yes. Agree how security findings enter your change process and what evidence those teams need. Security engineering supports their work; it does not replace their assessment or approval authority.
Yes. A defined research workspace, application, access process, provider connection, or recovery scenario can be a practical starting point. Agree boundaries and representative evidence before expanding.
Potential scope includes research platforms, electronic lab notebooks, laboratory information management systems, electronic data capture, electronic trial master files, quality applications, cloud services, and approved manufacturing-support integrations. Confirm products, versions, access, permissions, and necessary expertise during scoping.
Only within the authorisation and rules that apply. Reviewing your tenant settings or custom integration does not grant permission to test a provider's shared infrastructure or another customer's environment.
Use approved test roles and synthetic data where possible. Clinical owners define access boundaries and any blinded or unblinded roles. Do not expose allocation information or modify live study records during routine testing.
Only where specifically scoped with the required technical expertise and owner approval. Methods must suit the equipment and operational constraints. Physical inspection, specialist testing, and site access need separate arrangements.
An engineer can identify exposures and prepare proposed changes. Execution depends on approved change control, vendor constraints, impact assessment, and any validation work required by your responsible teams.
No. It can provide technical findings and evidence for a scoped assurance review. Applicability and wider procedural, validation, and quality requirements must be assessed by qualified owners. It does not provide a universal compliance certificate.
Agree authorisation, target systems, accounts, timing, data, stop conditions, and escalation contacts. Prefer an appropriate test environment and coordinate any production activity with the system owners. Do not assume ordinary IT scans are suitable for instruments or production controls.
Where your setup permits, work can use approved remote access and client-controlled repositories. Agree what may be viewed, copied, retained, or exported. Remote viewing still needs appropriate access and data handling approval.
Establish restrictions before accepting the scope. Some work may use approved minimised evidence or alternative delivery arrangements; other activities may not be suitable for offshore access. Do not assume contractual or geographic restrictions disappear through remote access.
We can help organise agreed security evidence, findings, and remediation status. Audit, inspection, and regulatory outcomes depend on the wider system and organisation; they are not guaranteed by this service.
No. Agree working hours and escalation arrangements. Continuous monitoring and incident coverage require a separately staffed service with defined responsibilities, tools, and response commitments.
Specify both in the proposal. Fixes may require your developers, application provider, equipment vendor, or additional specialists. Agree who approves changes and what evidence establishes completion.
Immediate response is not implied by this page. Confirm responder availability, authority, and coordination with existing providers separately. Clinical, quality, legal, and other relevant owners may need to participate in the response.
Assess the specific tool, information, purpose, permissions, and data destinations before use. Security controls should accompany domain review and applicable governance. Do not send confidential documents to unapproved services.
No. It assesses agreed security behaviours and access boundaries. Scientific accuracy, clinical suitability, quality decisions, and regulatory acceptability require the appropriate experts and intended-use assessment.
Scope, access readiness, system complexity, specialist needs, testing depth, and working arrangements determine the proposal. Agree deliverables, approvals, retesting, and handover before starting rather than relying on a fixed universal timeline.
Contact and scoping call
Tell us where your pharmaceutical
business needs security support.
Discuss a research platform, clinical application, laboratory environment, supplier connection, recovery concern, or dedicated-engineer requirement.
Loading open times…
Open times
Select an available date above to view open 45-minute times from our calendar.